Skip to main content

Table 1 Clinicopathologic correlation of p-mTOR expression in gastric cancer

From: Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer

Factors

All patients

No. of patients (%)

P

 

N= 181(%)

mTOR negative

mTOR positive

 

Age(y)

   

.256

< 60

95(52.5)

50(56.8)

45(48.4)

 

≥60

86(47.5)

38(43.2)

48(51.6)

 

Sex

   

.926

Male

129(71.3)

63(71.6)

66(71.0)

 

Female

52(28.7)

25(28.4)

27(29.0)

 

Site

   

.053

Upper

77(42.5)

33(37.5)

44(47.3)

 

Middle

28(15.5)

10(11.4)

18(19.4)

 

lower

74(40.9)

43(48.9)

31(33.3)

 

Diffuse

2(1.1)

2(2.3)

0(0.0)

 

Tumor size

   

.172

≤ 4 cm

63(34.8)

35(40.0)

28(30.1)

 

> 4 cm

118(65.2)

53(60.0)

65(69.9)

 

Borrmann type

   

.398

Early stage

7(3.9)

6(6.8)

1(1.1)

 

I

4(2.2)

2(2.3)

2(2.1)

 

II

65(35.9)

31(35.2)

34(36.6)

 

III

101(55.8)

47(53.4)

54(58.1)

 

IV

4(2.2)

2(2.3)

2(2.1)

 

grading

   

.999

1

4(2.2)

2(2.3)

2(2.1)

 

2

55(30.4)

27(30.7)

28(30.1)

 

3

116(64.1)

56(63.6)

60(64.5)

 

4

6(3.3)

3(3.4)

3(3.3)

 

Pathologic T classification

   

.168

T1

17(9.4)

12(13.6)

5(5.4)

 

T2

35(19.3)

18(20.5)

17(18.3)

 

T3

119(65.7)

55(62.5)

64(68.8)

 

T4

10(5.5)

3(3.4)

7(7.5)

 

Pathologic N status

   

.008

N negative

44(24.3)

29(33.0)

15(16.1)

 

N positive

137(75.7)

59(67.0)

78(83.9)

 

Pathologic stage (pTNM)

   

.026

I

26(14.4)

17(19.3)

9(9.7)

 

II

47(26.0)

28(31.8)

19(20.4)

 

III

100(55.2)

41(46.5)

59(63.4)

 

IV

8(4.4)

2(2.3)

6(6.5)

Â